AnaptysBio announces strategic collaboration with Merck & Co., Inc.

SAN DIEGO, CA – February 8, 2010

 

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to an undisclosed disease target.

 

Click here to read AnaptysBio's press release.